OTCMKTS:KHRNF

Khiron Life Sciences Competitors

$0.45
0.00 (-0.92 %)
(As of 04/9/2021 08:27 PM ET)
Add
Compare
Today's Range
$0.43
Now: $0.45
$0.46
50-Day Range
$0.33
MA: $0.46
$0.59
52-Week Range
$0.25
Now: $0.45
$0.65
Volume264,400 shs
Average Volume749,563 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Khiron Life Sciences (OTCMKTS:KHRNF) Vs. ABAHF, ACRGF, APPB, AYRSF, CANB, and CNTMF

Should you be buying KHRNF stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Khiron Life Sciences, including Abacus Health Products (ABAHF), Acreage (ACRGF), Applied Biosciences (APPB), Ayr Strategies (AYRSF), Can B (CANB), and Cansortium (CNTMF).

Abacus Health Products (OTCMKTS:ABAHF) and Khiron Life Sciences (OTCMKTS:KHRNF) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Abacus Health Products and Khiron Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abacus Health Products0000N/A
Khiron Life Sciences00103.00

Khiron Life Sciences has a consensus target price of $2.80, indicating a potential upside of 522.22%. Given Khiron Life Sciences' higher probable upside, analysts plainly believe Khiron Life Sciences is more favorable than Abacus Health Products.

Earnings and Valuation

This table compares Abacus Health Products and Khiron Life Sciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abacus Health ProductsN/AN/AN/AN/AN/A
Khiron Life SciencesN/AN/AN/AN/AN/A

Profitability

This table compares Abacus Health Products and Khiron Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abacus Health ProductsN/AN/AN/A
Khiron Life SciencesN/AN/AN/A

Summary

Khiron Life Sciences beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

Khiron Life Sciences (OTCMKTS:KHRNF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Khiron Life Sciences and Acreage, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Khiron Life Sciences00103.00
Acreage01202.67

Khiron Life Sciences presently has a consensus target price of $2.80, indicating a potential upside of 522.22%. Acreage has a consensus target price of $8.4333, indicating a potential upside of 204.45%. Given Khiron Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Khiron Life Sciences is more favorable than Acreage.

Valuation and Earnings

This table compares Khiron Life Sciences and Acreage's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Khiron Life SciencesN/AN/AN/AN/AN/A
AcreageN/AN/AN/AN/AN/A

Profitability

This table compares Khiron Life Sciences and Acreage's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Khiron Life SciencesN/AN/AN/A
AcreageN/AN/AN/A

Summary

Khiron Life Sciences beats Acreage on 2 of the 3 factors compared between the two stocks.

Khiron Life Sciences (OTCMKTS:KHRNF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Khiron Life Sciences and Applied Biosciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Khiron Life Sciences00103.00
Applied Biosciences0000N/A

Khiron Life Sciences presently has a consensus target price of $2.80, indicating a potential upside of 522.22%. Given Khiron Life Sciences' higher probable upside, equities analysts plainly believe Khiron Life Sciences is more favorable than Applied Biosciences.

Valuation and Earnings

This table compares Khiron Life Sciences and Applied Biosciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Khiron Life SciencesN/AN/AN/AN/AN/A
Applied BiosciencesN/AN/AN/AN/AN/A

Profitability

This table compares Khiron Life Sciences and Applied Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Khiron Life SciencesN/AN/AN/A
Applied BiosciencesN/AN/AN/A

Summary

Khiron Life Sciences beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Khiron Life Sciences (OTCMKTS:KHRNF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Khiron Life Sciences and Ayr Strategies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Khiron Life Sciences00103.00
Ayr Strategies01602.86

Khiron Life Sciences presently has a consensus target price of $2.80, indicating a potential upside of 522.22%. Ayr Strategies has a consensus target price of $34.8571, indicating a potential upside of 63.96%. Given Khiron Life Sciences' stronger consensus rating and higher probable upside, equities analysts plainly believe Khiron Life Sciences is more favorable than Ayr Strategies.

Valuation and Earnings

This table compares Khiron Life Sciences and Ayr Strategies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Khiron Life SciencesN/AN/AN/AN/AN/A
Ayr StrategiesN/AN/AN/AN/AN/A

Profitability

This table compares Khiron Life Sciences and Ayr Strategies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Khiron Life SciencesN/AN/AN/A
Ayr StrategiesN/AN/AN/A

Summary

Khiron Life Sciences beats Ayr Strategies on 2 of the 3 factors compared between the two stocks.

Khiron Life Sciences (OTCMKTS:KHRNF) and Can B (NASDAQ:CANB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Khiron Life Sciences and Can B, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Khiron Life Sciences00103.00
Can B0000N/A

Khiron Life Sciences presently has a consensus target price of $2.80, indicating a potential upside of 522.22%. Given Khiron Life Sciences' higher probable upside, equities analysts plainly believe Khiron Life Sciences is more favorable than Can B.

Valuation and Earnings

This table compares Khiron Life Sciences and Can B's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Khiron Life SciencesN/AN/AN/AN/AN/A
Can BN/AN/AN/AN/AN/A

Profitability

This table compares Khiron Life Sciences and Can B's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Khiron Life SciencesN/AN/AN/A
Can BN/AN/AN/A

Summary

Khiron Life Sciences beats Can B on 2 of the 2 factors compared between the two stocks.

Khiron Life Sciences (OTCMKTS:KHRNF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Khiron Life Sciences and Cansortium, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Khiron Life Sciences00103.00
Cansortium00103.00

Khiron Life Sciences presently has a consensus target price of $2.80, indicating a potential upside of 522.22%. Cansortium has a consensus target price of $1.20, indicating a potential upside of 41.18%. Given Khiron Life Sciences' higher probable upside, equities analysts plainly believe Khiron Life Sciences is more favorable than Cansortium.

Valuation and Earnings

This table compares Khiron Life Sciences and Cansortium's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Khiron Life SciencesN/AN/AN/AN/AN/A
CansortiumN/AN/AN/AN/AN/A

Profitability

This table compares Khiron Life Sciences and Cansortium's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Khiron Life SciencesN/AN/AN/A
CansortiumN/AN/AN/A

Summary

Khiron Life Sciences beats Cansortium on 1 of the 1 factors compared between the two stocks.


Khiron Life Sciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ABAHF
Abacus Health Products
0.4$4.84-5.4%$0.00N/A0.00Gap Up
Acreage logo
ACRGF
Acreage
1.2$2.77-0.9%$0.00N/A0.00
APPB
Applied Biosciences
0.5$0.25-92.0%$0.00N/A0.00High Trading Volume
Gap Down
AYRSF
Ayr Strategies
1.4$21.26-1.0%$0.00N/A0.00High Trading Volume
Gap Down
Can B logo
CANB
Can B
0.4$0.55-1.8%$0.00N/A0.00High Trading Volume
Cansortium logo
CNTMF
Cansortium
1.1$0.85-1.8%$0.00N/A0.00
Charlotte's Web logo
CWBHF
Charlotte's Web
1.3$4.51-0.8%$0.00N/A0.00
Choom logo
CHOOF
Choom
0.5$0.10-7.1%$0.00N/A0.00
CPHRF
Cipher Pharmaceuticals
1.2$1.08-0.5%$0.00N/A0.00Gap Up
CLS Holdings USA logo
CLSH
CLS Holdings USA
0.7$0.22-8.6%$0.00N/A0.00
Cosmos logo
COSM
Cosmos
0.5$5.80-0.9%$0.00N/A0.00
Cresco Labs logo
CRLBF
Cresco Labs
1.5$12.73-1.1%$0.00N/A0.00
Curaleaf logo
CURLF
Curaleaf
1.6$14.70-0.1%$0.00N/A0.00
HMDEF
DionyMed Brands
0.5$2.25-1.5%$0.00N/A0.00High Trading Volume
Easton Pharmaceuticals logo
EAPH
Easton Pharmaceuticals
0.5$0.00-29.4%$0.00N/A0.00Gap Up
Elixinol Global logo
ELLXF
Elixinol Global
0.8$0.15-3.4%$0.00N/A0.00Gap Up
EVIO
EVIO
0.6$0.00-3.7%$0.00N/A0.00Gap Down
Flower One logo
FLOOF
Flower One
0.4$0.28-3.2%$0.00N/A0.00Gap Up
Golden Leaf logo
GLDFF
Golden Leaf
0.5$0.05-5.0%$0.00N/A0.00
Green Growth Brands logo
GGBXF
Green Growth Brands
0.4$0.01-3.6%$0.00N/A0.00Gap Up
Green Thumb Industries logo
GTBIF
Green Thumb Industries
1.7$28.10-3.9%$0.00N/A0.00
GTEC logo
GGTTF
GTEC
0.6$0.62-3.4%$0.00N/A0.00Gap Down
Harvest Health & Recreation logo
HRVSF
Harvest Health & Recreation
1.3$3.06-2.0%$0.00N/A0.00
Hemp Naturals logo
HPMM
Hemp Naturals
0.6$0.01-3.3%$0.00N/A0.00
Hexo logo
HYYDF
Hexo
0.6$5.30-1.8%$0.00N/A0.00
Hikma Pharmaceuticals logo
HKMPY
Hikma Pharmaceuticals
0.4$59.68-4.6%$0.00N/A0.00Gap Up
iAnthus Capital logo
ITHUF
iAnthus Capital
0.6$0.24-7.5%$0.00N/A0.00Gap Up
Icanic Brands logo
ICNAF
Icanic Brands
0.6$0.36-0.6%$0.00N/A0.00
KNHBF
ICC International Cannabis
0.6$0.43-0.0%$0.00N/A0.00
Invictus MD Strategies logo
IVITF
Invictus MD Strategies
0.6$0.04-4.6%$0.00N/A0.00Gap Up
Isodiol International logo
ISOLF
Isodiol International
0.4$0.06-13.1%$0.00N/A0.00Gap Up
KHTRF
Knight Therapeutics
1.2$4.22-0.3%$0.00N/A0.00High Trading Volume
Marijuana Company of America logo
MCOA
Marijuana Company of America
0.5$0.01-3.6%$0.00N/A0.00News Coverage
Gap Down
Medical Marijuana logo
MJNA
Medical Marijuana
0.6$0.06-3.1%$0.00N/A0.00Gap Down
MediPharm Labs logo
MEDIF
MediPharm Labs
1.2$0.42-8.2%$0.00N/A0.00News Coverage
Gap Up
MedMen Enterprises logo
MMNFF
MedMen Enterprises
0.8$0.37-3.6%$0.00N/A0.00Gap Up
MERCK Kommanditgesellschaft auf Aktien logo
MKKGY
MERCK Kommanditgesellschaft auf Aktien
0.5$35.31-1.4%$0.00N/A0.00High Trading Volume
MJardin Group logo
MJARF
MJardin Group
1.1$0.07-2.6%$0.00N/A0.00Gap Up
MYHI
Mountain High Acquisitions
0.5$0.02-0.0%$0.00N/A0.00Gap Down
PHCEF
Pharmacielo
0.7$2.42-0.8%$0.00N/A0.00
Plus Products logo
PLPRF
Plus Products
1.1$0.57-0.9%$0.00N/A0.00Gap Down
Premier Biomedical logo
BIEI
Premier Biomedical
0.5$0.00-4.0%$0.00N/A0.00
PCYN
Procyon
0.4$0.70-7.1%$0.00N/A0.00Gap Up
Pure Global Cannabis logo
PRCNF
Pure Global Cannabis
0.7$0.01-5.5%$0.00N/A0.00
SANP
Santo Mining
0.5$0.01-7.2%$0.00N/A0.00News Coverage
Gap Down
Shionogi & Co., Ltd. logo
SGIOY
Shionogi & Co., Ltd.
0.5$13.39-1.6%$0.00N/A0.00
DNPUF
Sumitomo Dainippon Pharma
0.5$17.40-7.8%$0.00N/A0.00Gap Up
TerrAscend logo
TRSSF
TerrAscend
1.7$10.11-2.4%$0.00N/A0.00Gap Down
The Flowr logo
FLWPF
The Flowr
1.5$0.26-2.0%$0.00N/A0.00
The Supreme Cannabis logo
SPRWF
The Supreme Cannabis
1.0$0.32-0.8%$0.00N/A0.00Analyst Downgrade
News Coverage
Gap Up
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.